The Dime

Hosted by Bryan Fields

Business Entrepreneurship ScienceInterviews guests

Website RSS feed

Episodes

307

Latest episode

Oct 2026

Language

About the show

Most cannabis companies won't survive the next three years. The ones that do will have better capital discipline, sharper regulatory reads, and operational frameworks built for compression, not growth. The Dime is where cannabis operators, executives, and investors hear directly from the CEOs and founders making those decisions right now: MSO strategy, state-by-state market dynamics, cultivation and extraction economics, brand positioning, and the financing structures keeping companies alive. Bryan Fields hosts weekly conversations built for operators, not observers.

Listen to episodes

60 recent

October 26, 202644 min

How AYRLOOM Built Its Advantage in New York Cannabis ft. Eddie Brennan

A 115-year farm discovered that preserving the legacy meant letting a new crop compete with it. Ayrloom reached Beak & Skiff's revenue scale in three years, then forced the family to reallocate capital, people, land, and drying space while cannabis regulation kept the businesses legally separate. The advantage was not cannabis expertise. It was years of beverage manufacturing scars, retail-grade quality systems, and relationships strong enough to survive a crowded New York shelf. This week we sit down with Eddie Brennan Capital behind rapid growth Quality before repeat purchase Defending premium through compression Chapters 00:00 Sharing one farm across two companies 02:18 Cannabis versus apples for space 04:24 Three-year growth catches a 115-year business 07:33 Growth, cash, and what breaks 09:52 Why cannabis expertise is overrated 12:09 Beverage scars become an operating advantage 15:17 Grocery-grade quality control 19:10 Consistency wins repeat purchase 21:04 Making cannabis approachable 23:43 The reverse gateway claim 25:29 Where cannabis beverages belong 27:22 Regulation and high-dose drinks 30:14 Why Ayrloom stays narrow and deep 34:22 Price compression and retail health 37:05 When an in-house brand outruns co-manufacturing 39:39 What changes in a new market 42:10 The pressure of a fifth-generation legacy 44:35 Where to find Ayrloom Guest Links Eddie Brennan - ayrloom Our Links The Dime Podcast — website Bryan Fields on X The Dime on X The Dime on YouTube The Dime on Instagram Newton Insights — insights for extraction teams Follow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator rethinking their edibles. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

October 14, 202653 min

Who Benefits From Federal Cannabis Limbo? ft. Jay Rosenthal

Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise. The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge. This week we sit down with Jay Rosenthal Limbo as a moat EU GMP advantage Regulation's hidden winners Chapters 00:00 Federal limbo becomes the business model 02:17 The reform everyone agrees on 03:28 Capital markets and the bigger pond 05:35 Six hundred brands and no patience 06:55 Why Rochester can move New York 09:48 Strong operators become obvious 13:40 The cost of crossing state lines 16:28 Aurora Curaleaf and scarce EU GMP assets 20:26 The Canadian future that did not arrive 22:00 What mature industry compliance could bring 24:35 Cultivated's nonsecret sauce 31:41 Cannabis stigma still follows the operator 32:28 Why Cultivated launched membership 40:23 Quality media has a real cost 41:18 California and New York regulators share a market 44:02 Policy goals that fight each other 49:06 Competition cooperation and price compression 52:25 Where to find Jay and Cultivated Guest Links Jay Rosenthal - Co-Founder and Managing Director of Cultivated Media Cultivated Media Cultivated events Sign up for the Cultivated Daily newsletter Our Links The Dime Podcast — website Bryan Fields on X The Dime on X The Dime on YouTube The Dime on Instagram Newton Insights — insights for extraction teams Follow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator rethinking their edibles. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

September 30, 202642 min

What Makes Consumers Buy the Same Edible Again? ft. Kim Sanchez Rael

Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time. This week we sit down with Kim Sanchez Rael Fast onset economics The nano problem Science/ AI and so much more Fast-acting cannabis edibles promise a more predictable experience, but the language on the package does not always tell operators what happens in the final product. Kim Sanchez Rael, President and CEO of Azuca, breaks down what "fast" should mean, why slow-onset edibles still dominate, and how formulation choices affect taste, stability, curing time, shelf life, and production efficiency. She explains why "nano" is often a measurement or marketing label rather than proof of a better consumer outcome, then offers four questions brands should ask any infusion supplier. The conversation also moves beyond formulation. Kim describes the economics behind fast-acting products, the role of supplier behavior when production is at risk, the case for a single regulatory framework for the cannabis plant, and why operators cannot build a business that depends on an unpredictable regulatory change. Topics include: The consumer value of predictable onset Manufacturing tradeoffs in gummy formulation What brands should demand from infusion partners Why structured quality systems matter How Azuca uses AI inside its team and customer experience Learn more about Azuca and TiME INFUSION® at https://azuca.co/ . Guest: Kim Sanchez Rael, President and CEO, Azuca Host: Bryan Fields, The Dime Chapters 00:01 Why slow-onset edibles still dominate 01:47 The economics of fast acting 03:56 Can brands claim "fast"? 05:56 Predictability and consumer trust 08:06 The retail education gap 10:24 How Azuca licensing works 14:44 Formulation, cannabinoids, and flavor 15:30 When "fast" does not feel fast 18:18 Onset, peak, and duration 20:01 Manufacturing efficiency R&D 23:14 Validating infusion science 24:43 Why "nano" is a buzzword 27:38 The operational cost of change 28:24 Four questions for infusion suppliers 30:00 Supplier behavior as brand experience 32:31 The Fourth of July production rescue 33:48 What cannabis still gets wrong 34:15 The One Plant Solution 37:04 Policy resistance and incrementalism 38:41 AI and "Kimothy" 41:21 Quality systems and sustainable math 44:58 The question Kim wishes people asked 45:45 Where to find Azuca Our Links The Dime Podcast — website Bryan Fields on X The Dime on X The Dime on YouTube The Dime on Instagram Eighth Revolution Newton Insights — insights for extraction teams Follow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator rethinking their edibles. Guest Links Kim Sanchez Rael — Azuca Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

September 16, 202648 min

Europe Is Not a Rescue Plan ft. Jamie Pearson

Global expansion is often pitched as an opportunity. For an undisciplined cannabis company, it is an expensive way to expose every weakness at once. International markets reward specific operating capabilities, not ambition alone. Pharmaceutical standards, reliable supply, disciplined data use, and local market fit determine whether an operator can cross borders without compounding its problems. This week we sit down with Jamie Pearson EU GMP's undervalued strategic value Regulation exposes operating weakness Matching strength to global markets On The Dime, host Bryan Fields speaks with Jamie L. Pearson, President and Founder of New Holland Group, about European cannabis expansion, medical cannabis supply chains, and building operations that can succeed across borders. Key Takeaways Jamie explains why European medical cannabis markets call for pharmaceutical reliability, consistent supply, and a different operating model from adult-use brands. EU GMP (European Union Good Manufacturing Practice) capability can be a strategic asset for cannabis manufacturing and international market entry. Match the company's repeatable strengths to local buyers, regulations, and supply chains before choosing a market. Prove standard operating procedures (SOPs) and quality controls in another U.S. state before adding language, currency, and cross-border complexity. The discussion spans the UK, Germany, Switzerland, Slovenia, Portugal, and Brazil, alongside cannabis data and U.S. hemp regulation. Chapters 00:00 Regulation is breaking the data layer 02:49 Finding trend data upstream 06:24 What EU GMP actually demands 10:19 Why compliant facilities become strategic assets 16:13 Canada-Europe regulatory harmony 19:20 Europe is medical first 25:28 First-mover advantage vs. disciplined execution 27:59 Medical supply rewards repeatability 30:48 Weak operations do not travel 32:24 Switzerland, Slovenia, and Portugal 35:54 Brazil and partner requirements 37:07 Practice expansion before global scale 40:08 The hidden U.S. hemp market 43:29 Turning customers into political force 47:10 Directness as respect Guest Links Jamie L. Pearson — official bio New Holland Group New Holland Group on LinkedIn Related Episode Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka — continue exploring Germany's cannabis market and operational discipline. Our Links The Dime Podcast — website Bryan Fields on X The Dime on X The Dime on YouTube The Dime on Instagram Eighth Revolution Newton Insights — insights for extraction teams Follow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator considering expansion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

August 4, 202653 min

Paige Figi: The Cannabis Industry Is Cheering A Ban On Medicine

Much of the licensed cannabis industry is quietly counting the volume it expects to inherit from the federal hemp ban coming this November. ** Now December. What they may not realize is that the ban could eliminate the full-spectrum therapeutic hemp formulations that helped change America's view of cannabis and are used daily by an estimated 45 million Americans. The provision was written by two members of Congress, without a conference or regular order, and inserted into a massive spending bill during the longest government shutdown in American history. What should have been handled with a scalpel was done with a sledgehammer. This week we sit down with Paige Figi to discuss • Silence is a position • The scalpel Congress skipped • Oval Office, then banned Chapters 00:00 Introduction to the legislative landscape of cannabis 00:21 The impact of Charlotte's story on cannabis perception 00:48 Distinguishing hemp from marijuana in legislation 02:11 The challenges of passing therapeutic hemp laws 02:52 Congress's need for simple, effective regulation 03:48 The slow progress of therapeutic hemp legalization 04:53 The importance of clear plant distinctions 05:56 The November 12 hemp ban and its implications 07:02 The dangers of Franken hemp and synthetic cannabinoids 08:00 The public health emergency posed by recent bans 08:49 The role of science and data in regulation 10:13 The importance of industry and public unity 10:58 How regulations can support medical and adult use 12:06 The impact of federal bans on patients and consumers 13:00 The need for a balanced, science-based approach 14:00 The political landscape and legislative hurdles 14:53 The power of public advocacy and individual action 16:07 The future of cannabis regulation and industry alignment 17:06 How to effectively communicate with policymakers 18:03 The importance of clear, science-backed legislation 19:00 The role of the FDA and federal agencies 20:01 The potential for bipartisan support and progress 21:08 The significance of the November 12 deadline 22:06 The ongoing fight for access and regulation 23:04 The moral and ethical considerations in cannabis policy 23:49 How consumers can influence policy change 24:47 The importance of unity within the industry 25:46 The potential for a balanced, effective regulatory framework 27:06 The role of science and data in shaping policy 28:03 The need for responsible, clear regulations 29:02 The future outlook for therapeutic hemp and CBD 30:02 Final thoughts and call to action Guest Links https://www.coalitionforaccess.org/ https://www.instagram.com/paigefigi/ https://realmofcaring.org/about/paige-figi/ Our Links Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev) , we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

July 9, 202650 min

Understand This Before You Use AI To Build Software ft. Chris Guthrie

AI has made software easier than ever to build. That does not mean every internal tool should become the backbone of your business. In this episode, Bryan sits down with Chris Guthrie to break down the growing temptation inside cannabis companies to vibe code internal tools, dashboards, CRMs, ERPs, and operational systems in the name of saving money. The problem is not the first version. The problem is what happens two months later, when a field does not map, the workflow breaks, the person who built it is unavailable, and a production team is now relying on code nobody fully understands. Chris explains the difference between a useful AI-built prototype and an enterprise-grade system that can survive real operators, messy data, security needs, compliance, multiple departments, M&A diligence, and future FDA-style requirements. This conversation covers why descriptive data does not create predictive insight, why Google Sheets to vibe coding can become a path to failure, and why the real AI opportunity starts after the business has clean data, clean processes, and a system strong enough to trust. This episode covers: The weekend build that fails Descriptive data will not predict Clean books before M&A Chapters 00:00 The Rise of AI in Software Development 03:07 Challenges of Internal Software Development 06:09 Understanding What 'Works' in Software 09:10 The Risks of Vibe Coding 12:05 The Importance of Established Infrastructure 14:58 Cost Considerations in Software Development 17:56 Predictive Insights and Data Utilization 21:13 Defining Core Business Focus 23:17 The Challenges of AI Implementation 27:00 Understanding AI's Limitations 28:58 The Importance of Data Governance 31:11 Navigating Change Management in Cannabis 35:51 Preparing for Industry Evolution 40:09 The ROI of ERP Systems Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev) , we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

June 25, 20261 hr 11 min

Hirsh Jain: Rescheduling Is Already Picking Winners

Cannabis rescheduling is not as simple as “Trump rescheduled cannabis.” States are interpreting rescheduling completely differently depending on their license structure. These tiny details are widening the gap between potential winners and losers. In this episode, we break down what actually changed, what is still unresolved, and why rescheduling may already be picking winners and losers. This week, we sit down with Hirsh Jain to discuss: • What the April order and June 29 hearing actually mean • How the DEA registration portal could impact operators • The three pathways for interstate commerce • Why state license structure may determine who is positioned for a national market Chapters 00:00 Understanding Cannabis Rescheduling 02:53 The Implications of Medical vs. Adult Use Cannabis 05:48 Navigating Federal Legality for Medical Cannabis 09:03 DEA Registration: A New Era for Cannabis Businesses 11:53 The Complexities of DEA Registration 15:02 Interstate Commerce: The Future of Cannabis Trade 17:46 State Models and Their Impact on Cannabis Regulation 21:02 Winners and Losers in the Cannabis Market 24:04 The Role of Politics in Cannabis Regulation 27:01 The Future of Interstate Commerce in Cannabis 38:15 Understanding the Dormant Commerce Clause 40:46 Interstate Commerce and Political Friction 42:43 Legal Challenges to Cannabis Rescheduling 44:37 The April Order and Its Implications 51:05 Upcoming Hearings and Their Significance 59:22 Emerging Markets in Red States 01:05:34 Cultural Shifts and Legal Implications 01:10:16 Looking Ahead: Signals for Progress Guest Links: https://www.anandastrategy.com/ Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev) , we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

June 22, 202641 min

Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka

Predictable cash flow is the whole game. In cannabis, predictable is the one thing almost nobody has. Organigram CEO James Yamanaka came up over 20 years at British American Tobacco, where that discipline is the entire model. He thinks the opportunity starts there: trim the portfolio, stop chasing every trend, tighten the supply chain, lean on the science, and align operations. Germany's market could nearly double in the next two years, but capturing it will take more than expansion. This week we sit down with James Yamanaka, CEO of Organigram: A BAT perspective on cannabis Why chasing every trend loses money How the Sanity deal unlocks Germany Chapters: 00:00 Introduction to Organigram and BAT's Involvement 05:24 Shifting Perspectives: From BAT to Organigram 09:08 Understanding the Complexity of the Cannabis Market 13:12 Balancing Listening and Leadership 17:24 Data-Driven Decision Making in Cannabis 21:18 Strategic SKU Management and Market Forecasting 24:17 Leveraging BAT's Expertise in Cannabis 30:04 The Strategic Importance of the Sanity Deal 39:57 Navigating Regulatory Challenges in the Cannabis Industry Guest Links: https://www.linkedin.com/in/james-yamanaka-aaa32a/ https://www.organigram.ca/ Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev) , we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

June 11, 202647 min

Why Ohio Cannabis Is Built Different: Inside the Regulator-Operator Alignment That's Actually Working ft. Caroline Henry

When a regulator asks what the downside is of adding one more testing requirement, what is the downside? Just a little more safe. Just in case. Especially when adding one more item to an already exhaustive testing panel. That logic is how licensed cannabis markets end up buried under compliance layers copied from other states, calibrated to someone else's problems. It is also exactly how two adjacent markets with nearly identical consumer bases, Ohio and Michigan, ended up with completely different market structures. What they do not share is regulatory philosophy. When one state watches another add a rule and asks itself whether it should do the same, the answer it lands on shapes the entire cost structure of every licensed operator inside its borders. Ohio learned to ask the follow-up question. Most states never do. Ohio closed the intoxicating hemp loophole on March 20th, ahead of the federal government, and those shops are starting to close. The next unlock may already be here: THC beverages reaching the customers who will never walk into a dispensary, sold at the restaurant down the street. This week we sit down with Caroline Henry, VP of Government and Regulatory Affairs at Buckeye Relief. The regulator FOMO problem Ohio vs. Michigan: two markets, one lesson THC beverages as the dispensary gateway Chapters 00:00 The Disconnect in Cannabis Perception 03:12 Navigating Stigma and Misconceptions 05:48 Regulatory Challenges and Industry Standards 08:55 Building Relationships with Regulators 11:54 Small Wins in Regulatory Negotiations 15:02 The Impact of Over-Regulation 17:48 Child-Resistant Packaging and Its Irony 25:38 Navigating Regulatory Challenges in the Cannabis Industry 26:00 The Role of Beverages in Reducing Stigma 30:37 Learning from Michigan: Ohio's Cannabis Strategy 39:31 Focusing on Ohio: The Case for Local Expertise 44:00 The Realities of Working in the Cannabis Industry Guest Links www.buckeyerelief.com www.amplifydispensary.com Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev) , we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

May 21, 202650 min

Cannabis Was Medicine. Now the Proof Is Catching Up, ft. Joel Stanley and Dr. Marcel Bonn-Miller

The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention. CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could actually support. That gap created a backlash the legitimate medical thesis didn't deserve. What's left on the other side of the green rush is a near-complete forgetting of the reason this industry started in the first place. The medicine. Now the infrastructure to prove it is finally in place. Standardized genetics. Reproducible extraction. Full compound characterization. An FDA botanical drug pathway that has existed since 2016 that most investors have never heard of. Organic medicine versus synthetic single-molecule will be a real choice at the pharmacy counter sooner than most people expect. The foundational work is already here. This week we sit down with Joel Stanley and Dr. Marcel Bonn-Miller: Botanical drugs vs. supplements 6,000 compounds, one drug Novel compounds nobody has named yet Chapters 00:00 Why Medical Validation Remains a Challenge for Cannabis 00:12 The FDA Approval Process for Plant-Based Medicines 01:03 Historical Market Dynamics and Their Impact on Cannabis Perception 02:48 Removing the Veil: How Science Can Validate Cannabinoid Therapies 03:15 The Complexity of Plant Molecules and Real-World Evidence 06:20 Focus in Drug Development: The Case of Autism Spectrum Disorder 07:10 The Impact of Charlotte's Web and Media Hype 08:52 Balancing Hype and Reality in Cannabinoid Medicine 10:01 Legitimization of Cannabis Research in Academia 12:10 The Evolution of Cannabis Research and Acceptance 13:54 The Future of Botanical Medicine and Academic Research 16:15 The Long Road of Drug Development for Cannabis-Based Medicines 20:50 Introducing AJA-001: A Botanical Drug for Autism 22:44 Standardization and Characterization of Botanical Drugs 24:01 Partnerships and Funding in Botanical Drug Development 24:40 Challenges of Multi-Compound Botanical Drugs 27:28 Reproducibility and Quality Control in Botanical Manufacturing 29:06 FDA Pathways for Botanical Drugs and New Chemical Entities 34:29 Identifying and Characterizing Thousands of Plant Compounds 39:48 The Role of AI and Supercomputing in Drug Discovery 41:11 Balancing Exploration and Focus in Botanical Research 44:38 What the World Will Understand About Cannabinoids in 10 Years 47:24 The Promise of Botanical Medicine Over Single Molecule Drugs Guest Links: AJNA Biosciences Website https://ajnabiosciences.com/ AJNA Biosciences LinkedIn https://www.linkedin.com/company/ajna-biosciences/posts/?feedView=all AJNA Biosciences Instagram @ajnabiosciences Charlotte’s Web Website https://www.charlottesweb.com/ Charlotte’s Web LinkedIn https://www.linkedin.com/company/charlottesweb/posts/?feedView=all Charlotte’s Web Instagram @charlotteswebcbd Joel Stanley LinkedIn https://www.linkedin.com/in/joel-stanley-2885116b/ Joel Stanley Instagram @joel.stanley Dr. Marcel Bonn-Miller LinkedIn https://www.linkedin.com/in/marcel-bonn-miller-897a581/ Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev) , we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Is this your show?

Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.

Claim this listing

More Business podcasts

The Bottom Line

Alexander Spencer

BusinessInterviews guests